The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease.
Yuani M RomanAdrian V HernandezC Michael WhitePublished in: The Annals of pharmacotherapy (2020)
Patients at high risk of recurrent cardiovascular disease events with an hs-CRP of 2 mg/L or greater can reduce the occurrence of ASCVD events with canakinumab or colchicine therapy. Colchicine is the preferable option, in particular for those with myocardial infarction, given its more reasonable cost.